FindTrial
Sign In

Leucovorin (Calcium Folinate)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Revolution Medicines, Inc.

Conditions

NeoplasmsPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic AdenocarcinomaPancreatic Adenocarcinoma MetastaticPancreatic Adenosquamous CarcinomaPancreatic CancerPancreatic Cancer Metastatic

Phase 1

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
CompletedNCT02720068
Merck Sharp & Dohme LLCNeoplasms
Start: 2016-05-02End: 2024-03-15Updated: 2025-05-30

Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
RecruitingNCT07621718
Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5
Start: 2026-05-22End: 2030-04-22Target: 670Updated: 2026-07-08

Related Papers

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.
2025-02-271 citations
3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff
Regular and Young Investigator Award Abstracts2023-10-31
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
Journal of Clinical Oncology2023-01-249 citations
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Journal of Clinical Oncology2021-05-2046 citations